Display options
Cite
Tanamachi Y, Saruwatari J, Noai M, et al. Possible association between moderate intellectual disability and weight gain in valproic acid-treated patients with epilepsy. Neuropsychiatr Dis Treat. 2015;11:1007-14doi: 10.2147/NDT.S80898.
Tanamachi, Y., Saruwatari, J., Noai, M., Kamihashi, R., Soraoka, H., Yoshimori, Y., Ogusu, N., Oniki, K., Yasui-Furukori, N., Ishitsu, T., & Nakagawa, K. (2015). Possible association between moderate intellectual disability and weight gain in valproic acid-treated patients with epilepsy. Neuropsychiatric disease and treatment, 111007-14. https://doi.org/10.2147/NDT.S80898
Tanamachi, Yukiko, et al. "Possible association between moderate intellectual disability and weight gain in valproic acid-treated patients with epilepsy." Neuropsychiatric disease and treatment vol. 11 (2015): 1007-14. doi: https://doi.org/10.2147/NDT.S80898
Tanamachi Y, Saruwatari J, Noai M, Kamihashi R, Soraoka H, Yoshimori Y, Ogusu N, Oniki K, Yasui-Furukori N, Ishitsu T, Nakagawa K. Possible association between moderate intellectual disability and weight gain in valproic acid-treated patients with epilepsy. Neuropsychiatr Dis Treat. 2015 Apr 07;11:1007-14. doi: 10.2147/NDT.S80898. eCollection 2015. PMID: 25897238; PMCID: PMC4397927.
Copy Download .nbib Format: NLM
Share it on

Neuropsychiatr Dis Treat. 2015 Apr 07;11:1007-14. doi: 10.2147/NDT.S80898. eCollection 2015.

Possible association between moderate intellectual disability and weight gain in valproic acid-treated patients with epilepsy.

Neuropsychiatric disease and treatment

Yukiko Tanamachi, Junji Saruwatari, Madoka Noai, Ryoko Kamihashi, Hiromi Soraoka, Yuki Yoshimori, Naoki Ogusu, Kentaro Oniki, Norio Yasui-Furukori, Takateru Ishitsu, Kazuko Nakagawa

Affiliations

  1. Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.
  2. Department of Neuropsychiatry, Hirosaki University School of Medicine, Hirosaki, Japan.
  3. Kumamoto Saishunso National Hospital, Koshi, Japan ; Kumamoto Ezuko Ryoiku Iryo Center, Kumamoto, Japan.
  4. Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan ; Center for Clinical Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.

PMID: 25897238 PMCID: PMC4397927 DOI: 10.2147/NDT.S80898

Abstract

BACKGROUND: Although patients with moderate intellectual disability (ID) are known to have higher rates of being overweight and obese than those without ID, there are no current data regarding the relationship between ID and weight gain in epilepsy patients treated with valproic acid (VPA).

PATIENTS AND METHODS: The possible association between moderate ID and an overweight status at the time of initiation of VPA therapy (baseline) was investigated using a logistic regression analysis in 143 patients with epilepsy. Among the 119 nonoverweight patients at baseline, the longitudinal association between moderate ID and the weight status during VPA therapy was retrospectively examined using a Cox hazards regression analysis and the generalized estimating equations approach, while also paying careful attention to associations with other patient characteristics.

RESULTS: The proportion of patients with moderate ID was 52.4% among the 143 study subjects. The presence of moderate ID was not associated with an overweight status at baseline (P=0.762). Among the nonoverweight patients at baseline, 16 subjects were newly diagnosed as being overweight during treatment with VPA (3.6±2.1 years). The presence of moderate ID was significantly associated with the incidence of an overweight status after starting VPA therapy (adjusted hazard ratio =6.72, P=0.007). The patient age at baseline and treatment with co-administered carbamazepine, clobazam, and zonisamide significantly influenced the degree of weight fluctuation during VPA therapy among the patients with moderate ID (P<0.001, P<0.001, P=0.002, and P=0.028, respectively), whereas only patient age at baseline affected this parameter among the patients without moderate ID (P=0.022).

CONCLUSION: The present findings suggest that the weight status should be carefully monitored in VPA-treated patients with moderate ID, especially those receiving other co-administered antiepileptic drugs that facilitate weight gain, such as carbamazepine.

Keywords: antiepileptic drug; longitudinal analysis; obesity; overweight; weight status

References

  1. Am J Intellect Dev Disabil. 2011 Nov;116(6):401-18 - PubMed
  2. BMJ. 2000 May 6;320(7244):1240-3 - PubMed
  3. Obes Rev. 2011 May;12(5):e32-43 - PubMed
  4. Curr Diab Rep. 2014 Jul;14(7):507 - PubMed
  5. Res Dev Disabil. 2013 May;34(5):1417-25 - PubMed
  6. Clin Neurol Neurosurg. 2010 May;112(4):291-5 - PubMed
  7. Eur J Paediatr Neurol. 2014 Nov;18(6):747-58 - PubMed
  8. J Intellect Disabil Res. 1998 Dec;42 Suppl 1:1-15 - PubMed
  9. Epilepsia. 2008 Apr;49(4):608-14 - PubMed
  10. Obes Rev. 2011 Mar;12(3):189-97 - PubMed
  11. Pediatrics. 2014 Jun;133(6):e1586-93 - PubMed
  12. Epilepsia. 2011 Aug;52(8):1499-505 - PubMed
  13. Epilepsy Res. 2013 May;104(3):285-8 - PubMed
  14. Epilepsia. 2013 Aug;54(8):1473-80 - PubMed
  15. Clin Biochem. 2013 Oct;46(15):1323-38 - PubMed
  16. Epilepsia. 2010 Apr;51(4):676-85 - PubMed
  17. Epilepsy Behav. 2013 Oct;29(1):166-71 - PubMed
  18. Arq Neuropsiquiatr. 2010 Apr;68(2):277-81 - PubMed
  19. Epilepsia. 2007;48 Suppl 9:42-5 - PubMed
  20. Obes Rev. 2007 May;8(3):223-30 - PubMed
  21. Cochrane Database Syst Rev. 2014 Oct 04;(10):CD009258 - PubMed
  22. J Intellect Disabil Res. 2014 Mar;58(3):211-20 - PubMed
  23. Cell Mol Neurobiol. 2007 Dec;27(8):1069-83 - PubMed
  24. Epilepsy Res. 2013 Nov;107(1-2):1-8 - PubMed
  25. Epilepsy Res. 2013 Oct;106(3):301-10 - PubMed
  26. Sleep Med Rev. 2015 Feb;19:51-8 - PubMed
  27. Lancet Neurol. 2008 Jan;7(1):57-69 - PubMed
  28. Epilepsia. 2010 Feb;51(2):268-73 - PubMed
  29. Br Med J (Clin Res Ed). 1981 Aug 29;283(6291):577-81 - PubMed

Publication Types